Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Publication | Closed Access

DOI

575

Citations

References

2012

Year

Evan A. Stein, Dan Gipe, Jean Bergeron, Daniel Gaudet, Robert Weiss, Robert Dufour, Richard Wu, Robert Pordy

The Lancet

Metabolic SyndromeCardiovascular DiseaseStable Statin DoseLow-density Lipoprotein CholesterolHyperlipidemiaDyslipidemiaLipoprotein MetabolismMedicineAtherosclerosisMonoclonal Antibody